



2005: [Critical Path Institute](#) was formed as an independent nonprofit in response to the FDA's [Critical Path Initiative](#)

PUBLIC-PRIVATE PARTNERSHIP MODEL

1. Foster development of new evaluation tools to inform drug development and regulatory decision-making
2. Convene scientific consortia of industry, academia, and government for sharing of data/expertise



3. Enable iterative EMA/FDA/PMDA participation in developing new methods to assess the safety and efficacy of medical products
4. Obtain official regulatory endorsement of novel methodologies and drug development tools



DECREASING THE BURDEN OF DISEASE

UNMET MEDICAL NEED



C-Path expedites treatment in people of all ages, including both rare and non-rare conditions.

DDTs and Other Solutions

- Alpha-1 Antitrypsin Deficiency
- Alzheimer's Disease
- Amyotrophic Lateral Sclerosis
- Asthma
- Crohn's Disease
- Chronic Heart Failure
- Depression
- Duchenne Muscular Dystrophy
- Friedreich's Ataxia
- Functional Dyspepsia
- Huntington's Disease
- Irritable Bowel Syndrome
- Kidney Transplant
- Lysosomal Diseases
- Multiple Sclerosis
- Myelofibrosis
- Neonatal Conditions of Prematurity
- Non-small Cell Lung Cancer
- Parkinson's Disease
- Polycystic Kidney Disease
- Progressive Supranuclear Palsy
- Rheumatoid Arthritis
- Sickle Cell Disease
- Small Cell Lung Cancer
- Spinocerebellar Ataxia
- Tuberculosis and other infectious diseases
- Type 1 Diabetes

FDA ACKNOWLEDGEMENT



Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 54% funded by the FDA/HHS, totaling \$19,436,549, and 46% funded by non-government source(s), totaling \$16,373,368. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

<https://c-path.org/fda-acknowledgement>